Beyond Medical Announces Appointment of Michael Kelly to its Board of Director and is Working to Close the Final Tranche of Non Brokered Private Placement

 Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM3) is pleased to announce the appointment of Michael Kelly to the Company's board of directors, effective February 11, 2021 . Mr. Kelly replaces Bharat Bhushan, who has resigned as the Chief Technology Officer and as a director of the Company in order to pursue other opportunities. The Company would like to thank Mr. Bhushan for his contributions and wish him well in his future endeavours.

Taking Healthcare Beyond Traditional Platforms (CNW Group/Beyond Medical Technologies Inc.)

Mr. Kelly served over 17 years as a Military Police Officer with the Canadian Armed Forces. In 2001, Mr. Kelly left the Armed Forces to pursue a career with the Royal Canadian Mounted Police, serving in communities across British Columbia. Mr. Kelly retired from active service in 2015 and pursued his new passion of entrepreneurship. He has been a strategic partner to Bull Run Capital Inc. since 2015 and has become a respected investor and businessman in Kelowna , British Columbia.  Mr. Kelly brings a straightforward business approach with boundless enthusiasm and energy to the Company's board of directors.

Private Placement:
Beyond Medical recently announced the closing of the first tranch of its non brokered private placement for $5M . In the first tranche of the private placement, the company issued 10,580,000 units at a price of $0.125 per unit for gross proceeds of $1,322,500 . Each unit consists of one common share in the capital of the company and one share purchase warrant. Each warrant is exercisable to purchase one additional share at a price of 20 cents per warrant share until Feb. 5, 2023

Beyond Medical plans to close the final tranche of the non brokered placement in the coming weeks.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology. The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade facemasks compliant with ASTM F2100 Standards.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/February2021/11/c1893.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness and swelling. 1 If approved, teprotumumab would be the first and only medicine approved for TED in the European Union.

"We are enthusiastic to bring a much-needed medicine to the Thyroid Eye Disease community in Europe by leveraging Amgen's strong reputation and broad infrastructure in the region," said Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen. "This disease is currently managed with steroids and invasive surgeries, both of which carry their own set of risks. Having access to a non-surgical option like teprotumumab that not only treats the signs and symptoms, but also targets the underlying cause of the disease represents a major advance for patients."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Hydralyte

Waiver of ASX Listing Rule 10.1 Granted

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte North America or the Company) refers to its announcement dated 27 March 2024 (“27 March 2024 Announcement”) where the Company advised that it had signed a variation to its facility agreement with boutique asset manager and existing substantial shareholder PURE Asset Management Pty Ltd as trustee for The Income and Growth Fund (“PURE” or “PURE Asset Management”) (“Original PURE Facility”).

Keep reading...Show less
  BPH Global Ltd

Notice of Extraordinary General Meeting/Proxy Form

Notice is hereby given that an Extraordinary General Meeting of Shareholders of BPH Global Limited ACN 009 104 330 will be held at 3:00pm AEST on 24 May 2024 at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 (Meeting).

Keep reading...Show less
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less

Latest Press Releases

Related News

×